Balanced news tone
News Sentiment
AVTX sentiment intelligence
Avalo Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
57 relevant articles
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
+2.0% over one week, +30.1% over four weeks, trend active, and materially above fair value.
(AVTX) as a Liquidity Pulse for Institutional Tactics
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
79/100 classification
One-week reaction
2.0%
Price confirming higher
Trend fit
Trend active
30.1% over four weeks
Fair value
42.2%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
14
Neutral
40
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
Ron Philip joins Avalo Therapeutics (AVTX) board with stock option grant
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
MT Newswires
Direct company coverage
Avalo Therapeutics Plans IND Application for AVTX-010 in H1 2027
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 13:19
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 16 Jun 2026 11:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Avalo develops longer-lasting antibody to enable less frequent dosing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Avalo Therapeutics (AVTX) director awarded 29,500 options at $13.96 strike
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- Stock Titan
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
Affinity Asset Advisors discloses 5.5% stake in Avalo Therapeutics (NASDAQ: AVTX)
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 May 2026 07:00
- Source
- Stock Titan
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
GlobeNewswire
Direct company coverage
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- GlobeNewswire
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
FMR (AVTX) holds 2.88M shares of Avalo Therapeutics — 12.6% stake
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 May 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Avalo's skin disease drug beat placebo in Phase 2, heads to Phase 3
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Strong Phase 2 HS data for abdakibart boosts Avalo Therapeutics (NASDAQ: AVTX)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Avalo launches stock sale to fund Phase 3 abdakibart work
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Avalo prices $375M sale to fund drug development through Phase 3 data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Stock Titan
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 Apr 2026 07:00
- Source
- Market source
TradingView
Direct company coverage
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 06 Apr 2026 07:00
- Source
- TradingView
Stock Titan
Direct company coverage
65,800-share Form 144 filed by AVTX (NASDAQ: AVTX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Apr 2026 07:00
- Source
- Stock Titan
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
GlobeNewswire
Direct company coverage
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 23 Mar 2026 07:00
- Source
- GlobeNewswire
simplywall.st
Direct company coverage
Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely?
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 08 Nov 2025 08:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
Avalo Therapeutics (AVTX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 00:28
- Source
- Stock Titan
MarketBeat
Direct company coverage
Avalo Therapeutics (AVTX) Stock Forecast and Price Target 2026
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 11 May 2024 15:30
- Source
- MarketBeat